title: Synthetic ligands of death receptor 5 display a cell-selective agonistic effect at different oligomerization levels.
abstract: DR4 (Death Receptor 4) and DR5 (Death Receptor 5) are two potential targets for cancer therapy due to their ability to trigger apoptosis of cancer cells, but not normal ones, when activated by their cognate ligand TRAIL (TNF related apoptosis-inducing ligand). Therapies based on soluble recombinant TRAIL or agonist antibodies directed against one of the receptors are currently under clinical trials. However, TRAIL-R positive tumor cells are frequently resistant to TRAIL induced apoptosis. The precise mechanisms of this resistance are still not entirely understood. We have previously reported on synthetic peptides that bind to DR5 (TRAILmim/DR5) and induce tumor cell apoptosis in vitro and in vivo. Here, we showed that while hexameric soluble TRAIL is able to efficiently kill the DR5 positive lymphoma Jurkat or the carcinoma HCT116, these cells are resistant to apoptosis induced by the divalent form of TRAILmim/DR5 and are poorly sensitive to apoptosis induced by an anti-DR5 agonist monoclonal antibody. This resistance can be restored by the cross-linking of anti-DR5 agonist antibody but not by the cross-linking of the divalent form of TRAILmim/DR5. Interestingly, the divalent form of TRAILmim/DR5 that induced apoptosis of DR5 positive BJAB cells, acts as an inhibitor of TRAIL-induced apoptosis on Jurkat and HCT116 cells. The rapid internalization of DR5 observed when treated with divalent form of TRAILmim/DR5 could explain the antagonist activity of the ligand on Jurkat and HCT116 cells but also highlights the independence of the mechanisms responsible for internalization and activation when triggering the DR5 apoptotic cascade.
authors.affiliation: Institut de Biologie Moléculaire et Cellulaire, UMR 3572, Laboratoire d'Immunopathologie et Chimie Thérapeutique, Strasbourg 67084, France.|Current address: Khondrion BV, Nijmegen 6525EX, The Netherlands.
authors.forename: Julien
authors.initials: J
authors.lastname: Beyrath
authors.affiliation: Institut de Biologie Moléculaire et Cellulaire, UMR 3572, Laboratoire d'Immunopathologie et Chimie Thérapeutique, Strasbourg 67084, France.|Current address: Faculté de Pharmacie, UMR 7199, Laboratoire de Conception et Application de Molécules Bioactives, Illkirch BP 67401, France.
authors.forename: Neila
authors.initials: N
authors.lastname: Chekkat
authors.affiliation: Institut de Biologie Moléculaire et Cellulaire, UMR 3572, Laboratoire d'Immunopathologie et Chimie Thérapeutique, Strasbourg 67084, France.|Current address: University Medical Center Freiburg, Center for Chronic Immunodeficiency, Freiburg D-79110, Germany.
authors.forename: Cristian R
authors.initials: CR
authors.lastname: Smulski
authors.affiliation: Institut Européen de Chimie et Biologie, UMR 5248, Institut de Chimie & Biologie des Membranes & des Nano-objets (CBMN), Univ. Bordeaux, Pessac 33607, France.|UMR 5248, CBMN, CNRS, Pessac 33600, France.
authors.forename: Caterina M
authors.initials: CM
authors.lastname: Lombardo
authors.affiliation: Institut de Biologie Moléculaire et Cellulaire, UMR 3572, Laboratoire d'Immunopathologie et Chimie Thérapeutique, Strasbourg 67084, France.|Institut Européen de Chimie et Biologie, UMR 5248, Institut de Chimie & Biologie des Membranes & des Nano-objets (CBMN), Univ. Bordeaux, Pessac 33607, France.|UMR 5248, CBMN, CNRS, Pessac 33600, France.
authors.forename: Marie-Charlotte
authors.initials: MC
authors.lastname: Lechner
authors.affiliation: Current address: Faculté de Pharmacie, UMR 7199, Laboratoire de Conception et Application de Molécules Bioactives, Illkirch BP 67401, France.
authors.forename: Cendrine
authors.initials: C
authors.lastname: Seguin
authors.affiliation: Institut de Biologie Moléculaire et Cellulaire, UMR 3572, Laboratoire d'Immunopathologie et Chimie Thérapeutique, Strasbourg 67084, France.|UMR 5248, CBMN, CNRS, Pessac 33600, France.|UMR 5248, CBMN, Univ. Bordeaux, Pessac 33600, France.
authors.forename: Marion
authors.initials: M
authors.lastname: Decossas
authors.affiliation: Current address: Faculté de Pharmacie, UMR 7199, Laboratoire de Conception et Application de Molécules Bioactives, Illkirch BP 67401, France.
authors.forename: Maria Vittoria
authors.initials: MV
authors.lastname: Spanedda
authors.affiliation: Current address: Faculté de Pharmacie, UMR 7199, Laboratoire de Conception et Application de Molécules Bioactives, Illkirch BP 67401, France.
authors.forename: Benoît
authors.initials: B
authors.lastname: Frisch
authors.affiliation: Institut Européen de Chimie et Biologie, UMR 5248, Institut de Chimie & Biologie des Membranes & des Nano-objets (CBMN), Univ. Bordeaux, Pessac 33607, France.|UMR 5248, CBMN, CNRS, Pessac 33600, France.
authors.forename: Gilles
authors.initials: G
authors.lastname: Guichard
authors.affiliation: Institut de Biologie Moléculaire et Cellulaire, UMR 3572, Laboratoire d'Immunopathologie et Chimie Thérapeutique, Strasbourg 67084, France.|Current address: Faculté de Pharmacie, UMR 7199, Laboratoire de Conception et Application de Molécules Bioactives, Illkirch BP 67401, France.
authors.forename: Sylvie
authors.initials: S
authors.lastname: Fournel
mesh_terms: D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D017209:Apoptosis; D045325:HCT116 Cells; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D019169:Jurkat Cells; D008024:Ligands; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000378:metabolism* / Q000628:therapy; D009928:Organ Specificity; D055503:Protein Multimerization; D011940:Receptor Aggregation; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand / Q000276:immunology / Q000378:metabolism*; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000138:chemical synthesis / Q000378:metabolism* / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D008024:Ligands; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand; D053221:TNF-Related Apoptosis-Inducing Ligand; C105190:TNFRSF10A protein, human; C505639:TNFRSF10B protein, human; C505653:TNFSF10 protein, human; C548876:drozitumab
keywords: DR5; agonist; apoptosis; oligomerization; peptides